Development and Regulatory Aspects of Topical Dermatics Today
Organizer:
GD Society for Dermopharmacy
in cooperation with
BfArM Federal Institute for Drugs abd Medical Devices
Program (PDF)
Session 1: Dermatics – a world of its own
Session 2: Identification and production of active pharmaceutical ingredients
Session 3: Characterization of active pharmaceutical ingredients
Session 4: Aspects of formulation
Session 5: Clinical development
Session 2: Identification and production of active pharmaceutical ingredients
| Titel | Autor |
| Abstracts of sessions 1 and 2 | |
| Which dermatics do we have? | H. F. Merk, Aachen |
| Which dermatics do we need? | T. Luger, Münster |
| The regulatory framework for preclinical research | T. Zapf, Bonn |
| Target identification: general aspects and sphingosine-1-phosphate receptors as an example | B. Kleuser, Potsdam |
| Lead optimization: general aspects and MAP kinase inhibitors for psoriasis as an example | S. Laufer, Tübingen |
| Target identification and lead optimization: Fungal secreted aspartic proteinase inhibitors as a paradigm | C. Borelli, München |
| Production of active pharmaceutical ingredients: general aspects and sphingosine-1-phosphate and inhibitors of human polymerase alpha as an example | R. Zuhse, Luckenwalde |
Session 4: Aspects of formulation
| Titel | Autor |
| Abstracts for sessions 3 and 4 | |
| Toxicological characterization of new active pharmaceutical ingredients for dermatics | G. Hager, Tutzing |
| Pharmacological characterization of new active ingredients | T. Zollner, Berlin |
| Regulatory aspects of pharmaceutical quality with dermatics | B. Tofern-Reblin, Bonn |
| Optimizing conventional galenics: microemulsions as a paradigm | P. Schlupp, Gießen |
| Titel | Autor |
| Abstracts of session 5 | |
| Optimizing the development plan through scientific advice process | J. Regenold, Badenweiler |
| Human toxicology/phase I studies | J. Fluhr, Berlin |
| Phase II trials | B. Hughes-Formella, Hamburg |
| Phase III trials | K.-P. Wilhelm, Schenefeld |
| Phase IV trials | E. Blümner, Frankfurt am Main |
